MiNK Therapeutics, Inc. (INKT) Current Ratio
- Current ratio · latest quarter: Value 1.23×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.23× | Current assets / current liabilities. $9.30M ÷ $7.57M ≈ 1.23× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 9.30M USD | Assets, Current |
| Current obligations | 7.57M USD | Liabilities, Current |
| Cash and equivalents | 8.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.92M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.30M | $7.57M | $8.81M | (m) | (m) | (m) | $3.92M | (m) | 1.23× |
| 2026-03-31 | $10.02M | $7.29M | $9.53M | (m) | (m) | (m) | $3.39M | (m) | 1.38× |
| 2025-12-31 | $13.85M | $13.03M | $13.36M | (m) | (m) | (m) | $3.43M | (m) | 1.06× |
| 2025-09-30 | $14.53M | $13.43M | $14.28M | (m) | (m) | (m) | $3.69M | (m) | 1.08× |
| 2025-06-30 | $2.01M | $13.16M | $1.68M | (m) | (m) | (m) | $3.31M | (m) | 0.15× |
| 2025-03-31 | $3.58M | $12.12M | $3.23M | (m) | (m) | (m) | $2.66M | (m) | 0.30× |
| 2024-12-31 | $4.99M | $6.96M | $4.58M | (m) | (m) | (m) | $2.73M | (m) | 0.72× |
| 2024-09-30 | $6.58M | $7.40M | $6.33M | (m) | (m) | (m) | $2.36M | (m) | 0.89× |
| 2024-06-30 | $9.47M | $10.15M | $9.31M | (m) | (m) | (m) | $3.20M | (m) | 0.93× |
| 2024-03-31 | $6.00M | $11.11M | $5.82M | (m) | (m) | (m) | $3.49M | (m) | 0.54× |
| 2023-12-31 | $3.60M | $11.40M | $3.37M | (m) | (m) | (m) | $3.91M | (m) | 0.32× |
| 2023-09-30 | $6.47M | $10.39M | $6.40M | (m) | (m) | (m) | $4.28M | (m) | 0.62× |
| 2023-06-30 | $11.05M | $11.46M | $10.62M | (m) | (m) | (m) | $4.89M | (m) | 0.96× |
| 2023-03-31 | $15.52M | $11.25M | $14.89M | (m) | (m) | (m) | $6.00M | (m) | 1.38× |
| 2022-12-31 | $20.40M | $12.68M | $19.64M | (m) | (m) | (m) | $5.82M | (m) | 1.61× |
| 2022-09-30 | $24.46M | $18.45M | $24.16M | (m) | (m) | (m) | $5.17M | (m) | 1.33× |
| 2022-06-30 | $30.33M | $17.43M | $29.85M | (m) | (m) | (m) | $4.79M | (m) | 1.74× |
| 2022-03-31 | $35.48M | $18.83M | $34.69M | (m) | (m) | (m) | $3.73M | (m) | 1.88× |
| 2021-12-31 | $39.63M | $16.47M | $38.89M | (m) | (m) | (m) | $3.00M | (m) | 2.41× |
| 2021-09-30 | $3.44M | $80.56M | (m) | (m) | (m) | (m) | $1.65M | (m) | 0.04× |
| 2020-12-31 | $4.10M | $14.22M | (m) | (m) | (m) | (m) | $3.14M | (m) | 0.29× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |